574 related articles for article (PubMed ID: 21616722)
21. The role of satisfaction and switching costs in Medicare Part D choices.
Han J; Ko DW; Urmie JM
Res Social Adm Pharm; 2014; 10(2):398-407. PubMed ID: 23988694
[TBL] [Abstract][Full Text] [Related]
22. Comparing clinical and economic outcomes of biologic and conventional medications in postmenopausal women with osteoporosis.
Hernandez I; Zhang Y
J Eval Clin Pract; 2015 Oct; 21(5):840-7. PubMed ID: 26059485
[TBL] [Abstract][Full Text] [Related]
23. Minimizing out-of-pocket prescription drug costs for Medicare beneficiaries: not just 'a drop in the bucket'.
Patel RA; Vo KA; Chu T; Wang K; Lu S; Woelfel JA; Carr-Lopez SM; Galal SM
J Am Pharm Assoc (2003); 2014; 54(6):604-9. PubMed ID: 25379981
[TBL] [Abstract][Full Text] [Related]
24. Access to oral osteoporosis drugs among female Medicare Part D beneficiaries.
Lin CW; Karaca-Mandic P; McCullough JS; Weaver L
Womens Health Issues; 2014; 24(4):e435-45. PubMed ID: 24837398
[TBL] [Abstract][Full Text] [Related]
25. Changes in drug utilization during a gap in insurance coverage: an examination of the medicare Part D coverage gap.
Polinski JM; Shrank WH; Huskamp HA; Glynn RJ; Liberman JN; Schneeweiss S
PLoS Med; 2011 Aug; 8(8):e1001075. PubMed ID: 21857811
[TBL] [Abstract][Full Text] [Related]
26. Part D plan enrollment by uninsured medicare beneficiaries.
Maciejewski ML; Farley JF; Hansen RA; Wei D; Harman JS
Med Care; 2010 Feb; 48(2):183-6. PubMed ID: 20057332
[TBL] [Abstract][Full Text] [Related]
27. 2007 costs and coverage of antiretrovirals under Medicare Part D for people with HIV/AIDS living in North Carolina.
Sengupta S
N C Med J; 2008; 69(1):6-13. PubMed ID: 18429558
[TBL] [Abstract][Full Text] [Related]
28. Medicare Part D research highlights and policy updates, 2013: impact and insights.
Stubbings J; Lau DT
Clin Ther; 2013 Apr; 35(4):402-12. PubMed ID: 23541710
[TBL] [Abstract][Full Text] [Related]
29. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
Blumberg DM; Prager AJ; Liebmann JM
JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
[TBL] [Abstract][Full Text] [Related]
30. Potential impact of Medicare Part D in the end-stage renal disease population.
St Peter WL
Adv Chronic Kidney Dis; 2008 Apr; 15(2):140-6. PubMed ID: 18334238
[TBL] [Abstract][Full Text] [Related]
31. Characteristics of Medicare Part D beneficiaries who reach the drug benefit threshold in both of the first two years of the Part D benefit.
Bayliss EA; Ellis JL; Delate T; Steiner JF; Raebel MA
Med Care; 2010 Mar; 48(3):267-72. PubMed ID: 20125044
[TBL] [Abstract][Full Text] [Related]
32. Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase.
Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
J Manag Care Spec Pharm; 2014 Aug; 20(8):862-76. PubMed ID: 25062080
[TBL] [Abstract][Full Text] [Related]
33. Variation in estimated Medicare prescription drug plan costs and affordability for beneficiaries living in different states.
Davis MM; Patel MS; Halasyamani LK
J Gen Intern Med; 2007 Feb; 22(2):257-63. PubMed ID: 17356996
[TBL] [Abstract][Full Text] [Related]
34. Sociodemographic and spending characteristics of Medicare beneficiaries taking prescription drugs subject to price negotiations.
Odouard IC; Anderson GF; Alexander GC; Ballreich J
J Manag Care Spec Pharm; 2024 Mar; 30(3):269-278. PubMed ID: 38140901
[TBL] [Abstract][Full Text] [Related]
35. Medicare Part D's effects on elderly patients' drug costs and utilization.
Ketcham JD; Simon KI
Am J Manag Care; 2008 Nov; 14(11 Suppl):SP14-22. PubMed ID: 18991476
[TBL] [Abstract][Full Text] [Related]
36. Medicare Part D: challenges for dialysis patients. Part 1.
Smith S; Witten B; Paykin C; Weiner S; Chianchiano D; St Peter WL
Nephrol News Issues; 2011 Nov; 25(12):38-40, 42, 44-5. PubMed ID: 22204167
[TBL] [Abstract][Full Text] [Related]
37. Actual versus predicted first-year utilization patterns of teriparatide in patients with employer-sponsored health insurance.
Meadows ES; Rousculp M; Sasser AC; Birnbaum HG; Moyneur E; Mallet D; Johnston JA
Curr Med Res Opin; 2007 Dec; 23(12):3215-22. PubMed ID: 18021497
[TBL] [Abstract][Full Text] [Related]
38. Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis.
Borgström F; Ström O; Marin F; Kutahov A; Ljunggren O
J Med Econ; 2010; 13(3):381-92. PubMed ID: 20604678
[TBL] [Abstract][Full Text] [Related]
39. Changing patterns in medication use with increasing probability of death for older Medicare beneficiaries.
Shaffer T; Simoni-Wastila L; Toler W; Stuart B; Doshi JA
J Am Geriatr Soc; 2010 Aug; 58(8):1549-55. PubMed ID: 20670381
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer.
Ito K; Elkin E; Blinder V; Keating N; Choudhry N
Cancer; 2013 Jul; 119(13):2494-502. PubMed ID: 23775433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
